アトピー性皮膚炎（AD）に対するデュピクセント®投与患者の観察研究
基本情報
- NCT ID
- NCT03992417
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- -
- 試験タイプ
- 観察
- 目標被験者数
- 955
- 治験依頼者名
- Sanofi
概要
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants